Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.

ABSTRACT:

Importance

Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of visual disability in older individuals. A phase 2 trial suggested that lampalizumab, a selective complement factor D inhibitor, reduced the rate of GA enlargement, warranting phase 3 trials.

Objective

To assess the safety and efficacy of lampalizumab vs sham procedure on enlargement of GA.

Design, setting, and participants

Two identically designed phase 3 double-masked, randomized, sham-controlled clinical trials, Chroma and Spectri, enrolled participants from August 28, 2014, to October 6, 2016, at 275 sites in 23 countries. Participants were aged 50 years or older, with bilateral GA and no prior or active choroidal neovascularization in either eye and GA lesions in

SUBMITTER: Holz FG 

PROVIDER: S-EPMC6145777 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature